1. Home
  2. LEGN vs CFLT Comparison

LEGN vs CFLT Comparison

Compare LEGN & CFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • CFLT
  • Stock Information
  • Founded
  • LEGN 2014
  • CFLT 2014
  • Country
  • LEGN United States
  • CFLT United States
  • Employees
  • LEGN N/A
  • CFLT N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • CFLT EDP Services
  • Sector
  • LEGN Health Care
  • CFLT Technology
  • Exchange
  • LEGN Nasdaq
  • CFLT Nasdaq
  • Market Cap
  • LEGN 7.0B
  • CFLT 8.1B
  • IPO Year
  • LEGN 2020
  • CFLT 2021
  • Fundamental
  • Price
  • LEGN $32.38
  • CFLT $22.34
  • Analyst Decision
  • LEGN Strong Buy
  • CFLT Buy
  • Analyst Count
  • LEGN 13
  • CFLT 30
  • Target Price
  • LEGN $79.42
  • CFLT $31.00
  • AVG Volume (30 Days)
  • LEGN 1.5M
  • CFLT 6.6M
  • Earning Date
  • LEGN 05-13-2025
  • CFLT 04-30-2025
  • Dividend Yield
  • LEGN N/A
  • CFLT N/A
  • EPS Growth
  • LEGN N/A
  • CFLT N/A
  • EPS
  • LEGN N/A
  • CFLT N/A
  • Revenue
  • LEGN $627,241,000.00
  • CFLT $1,017,525,000.00
  • Revenue This Year
  • LEGN $65.96
  • CFLT $21.73
  • Revenue Next Year
  • LEGN $52.55
  • CFLT $18.93
  • P/E Ratio
  • LEGN N/A
  • CFLT N/A
  • Revenue Growth
  • LEGN 119.97
  • CFLT 24.11
  • 52 Week Low
  • LEGN $29.27
  • CFLT $17.79
  • 52 Week High
  • LEGN $60.87
  • CFLT $37.90
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 45.13
  • CFLT 51.08
  • Support Level
  • LEGN $30.25
  • CFLT $20.46
  • Resistance Level
  • LEGN $35.81
  • CFLT $24.50
  • Average True Range (ATR)
  • LEGN 1.43
  • CFLT 1.08
  • MACD
  • LEGN -0.14
  • CFLT 0.16
  • Stochastic Oscillator
  • LEGN 38.36
  • CFLT 60.00

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About CFLT Confluent Inc.

Confluent Inc provides a data streaming platform that enables customers to connect their applications, systems, and data layers and can be deployed as a fully managed cloud-native software-as-a-service (SaaS) offering. Its products include Confluent Cloud, a self-managed software offering, Confluent Platform, a managed service offering where the raw data resides inside a customer's cloud environment, and WarpStream, among others. Confluent also offers professional services and education services. The company generates revenue from the sale of subscriptions and services. Geographically, it generates a majority of its revenue from its business in the United States and the rest from International markets.

Share on Social Networks: